Get the Stockscreener App
403.75
0.40%
1.62
After Hours:
403.75
Overview
News
Price History
Option Chain
Financials
Why TMO Down?
Discussions
Forecast
Stock Split
Dividend History
Thermo Fisher Scientific Inc stock is traded at $403.75, with a volume of 2.50M.
It is up +0.40% in the last 24 hours and down -5.56% over the past month.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
See More
Previous Close:
$402.13
Open:
$403.05
24h Volume:
2.50M
Relative Volume:
1.04
Market Cap:
$152.41B
Revenue:
$42.90B
Net Income/Loss:
$6.52B
P/E Ratio:
23.68
EPS:
17.05
Net Cash Flow:
$6.72B
1W Performance:
+0.82%
1M Performance:
-5.56%
6M Performance:
-23.77%
1Y Performance:
-28.83%
1-Day Range:
$401.42
$407.37
1-Week Range:
$390.66
$407.75
52-Week Range:
$390.50
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Name
Thermo Fisher Scientific Inc
Sector
Industry
Phone
(781) 622-1000
Address
168 THIRD AVENUE, WALTHAM, MA
Compare TMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
403.75 | 151.18B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
190.47 | 134.17B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
515.55 | 40.60B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
113.28 | 31.27B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
141.02 | 23.88B | 15.50B | 1.33B | 2.16B | 7.34 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Mar-18-24 | Resumed | Citigroup | Neutral |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-08-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-26-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-25-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-06-23 | Resumed | Citigroup | Buy |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| Jul-19-23 | Reiterated | Robert W. Baird | Outperform |
| Jul-13-23 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-04-23 | Reiterated | Barclays | Overweight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-26-22 | Resumed | Barclays | Overweight |
| Oct-20-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Mar-18-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-14-20 | Initiated | Morgan Stanley | Overweight |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Jul-15-20 | Upgrade | Cleveland Research | Neutral → Buy |
| Jul-07-20 | Reiterated | Needham | Buy |
| Apr-23-20 | Reiterated | Needham | Buy |
| Jan-31-20 | Reiterated | Needham | Buy |
| Jan-22-20 | Initiated | Credit Suisse | Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-25-19 | Reiterated | Needham | Buy |
| Jul-16-19 | Downgrade | Needham | Strong Buy → Buy |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| May-23-19 | Reiterated | Needham | Strong Buy |
| Apr-22-19 | Reiterated | Needham | Strong Buy |
| Apr-16-19 | Reiterated | BofA/Merrill | Buy |
View All
Thermo Fisher Scientific Inc Stock (TMO) Latest News
Thermo Fisher Must Hand Over Pay Study to Worker Suing for Bias - Bloomberg Law News
Thermo Fisher Scientific launches new Spectral Flow Cytometer - BioSpectrum Asia
Ultra-Low Temperature Freezers Market Is Booming WorldwideThermo Fisher Scientific, PHCbi - openPR.com
Thermo Fisher Scientific Launches New Spectral Flow Cytometer Offering Increased Speed, Versatility and Reliability to Labs - BioSpace
Bioinformatics Market Detailed in New Research ReportThermo Fisher Scientific, Illumina - openPR.com
Lentiviral Vectors Market Set to Witness Increased DemandThermo Fisher Scientific, Merck KGaA - openPR.com
Thermo Fisher Scientific Celebrates Precision Oncology Advancement at ASCO 2025 - BioSpace
Thermo Fisher Scientific Stock: Big Upside Potential After Sluggishness Through November? - Benzinga
Biobank Market Deep Research with Forecast By 2025-2032 | Thermo Fisher Scientific Inc., BioLife Solutions - openPR.com
Agilent Poaches Top Thermo Fisher Executive to Lead Technology Innovation Strategy - Stock Titan
D-Amino Acids Market Report 2025-2030 Featuring Analysis of - GlobeNewswire
Sterilization Monitoring Market Surges Towards USD 1.31 Billion by 2030 Amid Rising Demand for Real-Time Validation - GlobeNewswire Inc.
Spectrometry Market is Booming WorldwideThermo Fisher Scientific, Agilent Technologies - openPR.com
Zacks Investment Ideas feature highlights: Thermo Fisher Scientific and Lululemon - Yahoo Finance
Bioreactors Market Generated Opportunities, Future Scope - openPR.com
Cell-Free DNA Isolation and Extraction Market - GlobeNewswire Inc.
Research Antibodies Market to Witness Remarkable Growth with - openPR.com
Mirai Bio Partners with Thermo Fisher to Integrate AI Design and CGMP Manufacturing for Genetic Medicines - geneonline.com
$1000 Invested In Thermo Fisher Scientific 10 Years Ago Would Be Worth This Much Today - Benzinga
2 S&P 500 Stocks to Buy Now On the Dip for Huge Upside - Yahoo Finance
Thermo Fisher introduces new narcotics analyzers - Wiley Analytical Science
Why Is Thermo Fisher (TMO) Down 6.1% Since Last Earnings Report? - Yahoo Finance
Thermo Fisher makes drug analyzer for law enforcement - The Business Journals
Thermo Fisher Scientific introduces next-generation TruNarc handheld narcotics analyzers - Police1
Cell and Tissue Preservation Market in 2025-2032 Detailed Study - openPR.com
Immune Cell Engineering Market Comprehensive Research Study - openPR.com
Thermo Fisher grants CEO performance-based stock units By Investing.com - Investing.com India
Thermo Fisher grants CEO performance-based stock units - Investing.com
Thermo Fisher Approves CEO’s $60M Stock Award - TipRanks
Thermo Fisher Scientific Grants 5-Year Performance-Based Restricted Stock Units To CEOSEC Filing - marketscreener.com
Thermo Fisher Scientific Inc. (NYSE:TMO) Q1 2025 Earnings Call Transcript - MSN
Thermo Fisher Scientific Introduces Next Generation TruNarc Handheld Narcotics Analyzers to Support Public Safety - BioSpace
Petri Dish: Thermo Fisher’s new partner; Waters buys California company - The Business Journals
Cybin Engages Thermo Fisher Scientific To Provide U.S.-Based Manufacturing for Its CYB003 Program - Technology Networks
Middleton TIF exception created for Thermo Fisher Scientific - MSN
Thermo Fisher Scientific Declares Quarterly DividendMay 21, 2025 - BioSpace
Thermo Fisher Scientific Keeps Quarterly Dividend at $0.43 a Share, Payable July 15 to Investors of Record June 13 - marketscreener.com
Thermo Fisher sets quarterly dividend at $0.43 per share - Investing.com
Thermo Fisher, Mirai Bio link up to advance and produce gene therapies - Fierce Pharma
Mirai Bio announces partnership with Thermo Fisher Scientific - European Pharmaceutical Manufacturer
Middleton approves resolution to support Thermo Fisher Scientific - WKOW
Mirai Bio Announces Strategic Collaboration with Thermo Fisher Scientific - marketscreener.com
Forensics and toxicologyIndustry Focus eBook - News-Medical
Mirai Bio Announces Partnership with Thermo Fisher Scientific to Accelerate Development of Genetic Medicines - PR Newswire
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 - MSN
Laboratory Clean Bench Market to See Stunning Growth with Esco, Thermo Fisher Scientific, Labconco - openPR.com
Thermo Fisher Scientific launches BSC with improved airflow and ergonomics - Cleanroom Technology
How Thermo Fisher’s KingFisher PlasmidPro crunches hours of plasmid Prep to 5 minutes hands-on - drugdiscoverytrends.com
Thermo Fisher no longer Massachusetts' most valuable company - NBC Boston
Market shift: Boston Scientific emerges as Massachusetts' most valuable public company - The Business Journals
DNA Synthesizer Market Key Players AnalysisThermo Fisher Scientific, Merck KGaA, Agilent Technologies - openPR.com
Thermo Fisher Scientific Inc Stock (TMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):